Oncology

The FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan introduces PSMA-targeted radioligand therapy to mHSPC.

World Lung Cancer Day presents an opportunity to recognize progress in lung cancer care while emphasizing the persistent need for earlier detection and equitable access to treatment.

Predictive scheduling can improve staffing, pharmacy preparation, infusion capacity, and the overall patient experience.

July 2026 brought major hematology advances in gene therapy, transplantation, targeted treatments, and bleeding disorder care, alongside notable clinical trial setbacks.

This roundup highlights 5 key solid tumor updates from July 2026, including new FDA approvals across bladder, breast, and lung cancers, a tissue-agnostic targeted therapy, and a blood-based colorectal cancer screening test.

The phase 2 AZTEC trial found that single- and multifraction SABR, followed by atezolizumab, had similar safety profiles and limited efficacy in advanced TNBC.

In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, discusses emerging bladder-preserving therapies for NMIBC, the limitations of single-arm trial data, the continued role of BCG, and the clinical and operational factors that should guide treatment selection.

Advance verification, multidisciplinary coordination, and AI-enabled forecasting can help infusion centers adjust schedules and treatment plans during chemotherapy shortages.

Angie Maynard, PharmD, MS, BCOP, discusses RCC immunotherapy guidelines, treatment selection, toxicity management, and pharmacists’ clinical role.

Subcutaneous isatuximab could compete with daratumumab in multiple myeloma by combining a hands-free, on-body delivery system with potential advantages in workflow, patient experience, and mechanisms of action.

Updated phase 1/2 findings showed that emavusertib-based therapy produced responses in both BTK inhibitor–naive and –treated patients with relapsed or refractory primary central nervous system (CNS) lymphoma.

Ravulizumab-cwvz did not significantly improve 26-week event-free survival in adults and adolescents with HSCT-associated thrombotic microangiopathy.

Adding consolidative thoracic radiotherapy to atezolizumab maintenance increased serious and fatal adverse events without improving survival in patients with ES-SCLC.

This week's episode covers a new AHA scientific statement on caffeine safety and cardiovascular benefit; pharmacist guidance for protecting patients with asthma, COPD, and allergies during wildfire smoke events; and regulatory updates in obstructive sleep apnea and ROS1-positive lung cancer.

Jordan Hill, PharmD, BCOP, discusses the expanded first-line role of sacituzumab govitecan in metastatic triple-negative breast cancer and how PD-L1 status informs its use alone or with pembrolizumab.

Holistic, integrative, functional, precision—the labels are everywhere, but few patients or clinicians know where one ends and the next begins.

Oncology pharmacy teams can integrate newly approved breast cancer therapies into practice while addressing operational barriers, monitoring requirements, and financial toxicity.

Cassandra Perkey, PharmD, BCOP, explains the operational, staffing, infrastructure, safety, and pharmacist-led requirements for successfully delivering CAR T-cell therapy in a community oncology setting.

GSK's next-generation ROS1 inhibitor earns approval after demonstrating durable responses in the ARROS-1 trial, including among patients with brain metastases.

Cassandra Perkey, PharmD, BCOP, discusses how pharmacists support community CAR T-cell programs through SOP development, treatment planning, education, emergency preparedness, and lessons learned from treating the first patient.

Adding palbociclib to anti-HER2 and endocrine maintenance therapy provides a new treatment option for patients with HR-positive, HER2-positive metastatic breast cancer.

In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, explains the staffing, infrastructure, hospital partnerships, and scheduling strategies needed to safely deliver outpatient CAR T-cell therapy in a community oncology setting.

Megan May, PharmD, BCOP, FHOPA, FAPO, discusses unanswered questions surrounding antibody-drug conjugate sequencing, biomarker testing, and medication safety in personalized breast cancer care.

Antibody-drug conjugates, evolving HER2 guidelines, and biomarker-driven treatment decisions are transforming breast cancer care and expanding the oncology pharmacist’s role.

A large US registry analysis found that men were more likely than women to be diagnosed with regional or distant disease across 20 nonreproductive cancer sites.

In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, discussed the patient selection, standardized workflows, toxicity management, payer coordination, and caregiver education needed to safely move bispecific step-up dosing into the outpatient setting.

In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, outlines the essential teams, SOPs, financial planning, and safety protocols community oncology practices need to launch outpatient CAR T-cell therapy successfully.

In an interview with Pharmacy Times, Cherise Steib, PharmD, HDDP, discussed patient selection, caregiver requirements, cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and the American Oncology Network’s approach to building an outpatient bispecific therapy program.